Identification of Two Novel Anti-Fibrotic Benzopyran Compounds Produced by Engineered Strains Derived from Streptomyces xiamenensis M1-94P that Originated from Deep-Sea Sediments
The benzopyran compound obtained by cultivating a mangrove-derived strain, Streptomyces xiamenensis strain 318, shows multiple biological effects, including anti-fibrotic and anti-hypertrophic scar properties. To increase the diversity in the structures of the available benzopyrans, by means of biosynthesis, the strain was screened for spontaneous rifampicin resistance (Rif), and a mutated rpsL gene to confer streptomycin resistance (Str), was introduced into the S. xiamenensis strain M1-94P that originated from deep-sea sediments. Two new benzopyran derivatives, named xiamenmycin C ( 1) and D ( 2), were isolated from the crude extracts of a selected Str-Rif double mutant (M6) of M1-94P. The structures of 1 and 2 were identified by analyzing extensive spectroscopic data. Compounds 1 and 2 both inhibit the proliferation of human lung fibroblasts (WI26), and 1 exhibits better anti-fibrotic activity than xiamenmycin. Our study presents the novel bioactive compounds isolated from S. xiamenensis mutant strain M6 constructed by ribosome engineering, which could be a useful approach in the discovery of new anti-fibrotic compounds.
References
[1]
Vlietinck, A.J.; de Bruyne, T.; Apers, S.; Pieters, L.A. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Med. 1998, 64, 97–109, doi:10.1055/s-2006-957384.
[2]
Borm, P. Toxicity of Selected: Toxicology of Fibers and Particles. In Proceedings of Toxicology and Risk Assessment, Heerlen, The Netherland, 14–17 April 2008; Greim, H., Snyder, R., Eds.; John Wiley & Sons Ltd.: Chichester, UK, 2008; pp. 565–583.
[3]
Wynn, T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214, 199–210, doi:10.1002/path.2277.
[4]
Friedman, S.L.; Sheppard, D.; Duffield, J.S.; Violette, S. Therapy for fibrotic diseases: Nearing the starting line. Sci. Transl. Med. 2013, 5, 1–17.
[5]
Wynn, T.A.; Ramalingam, T.R. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat. Med. 2012, 18, 1028–1040, doi:10.1038/nm.2807.
Evans, J.M.; Fake, C.S.; Hamilton, T.C.; Poyser, R.H.; Watts, E.A. Synthesis and antihypertensive activity of substituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols. J. Med. Chem. 1983, 26, 1582–1589, doi:10.1021/jm00365a007.
[8]
G？ker, H.; Boykin, D.W.; Y？ld？z, S. Synthesis and potent antimicrobial activity of some novel 2-phenyl or methyl-4H-1-benzopyran-4-ones carrying amidinobenzimidazoles. Bioorg. Med.Chem. 2005, 13, 1707–1714, doi:10.1016/j.bmc.2004.12.006.
[9]
Kawamura, N.; Tsuji, E.; Watanabe, Y.; Tsuchihashi, K.; Takako, T. Benzopyran Derivatives, Their Manufacture with Streptomyces Species, and Their Use for Treatment of Asthma and Rheumatoid Arthritis. Jpn. Patent P2000-726766A, 7 March 2000.
Tanaka, Y.; Kasahara, K.; Hirose, Y.; Murakami, K.; Kugimiya, R.; Ochi, K. Activation and products of the cryptic secondary metabolite biosynthetic gene clusters by rifampin resistance (rpoB) mutations in actinomycetes. J. Bacteriol. 2013, 195, 2959–2570, doi:10.1128/JB.00147-13.
[17]
Ochi, K.; Hosaka, T. New strategies for drug discovery: Activation of silent or weakly expressed microbial gene clusters. Appl. Microbiol. Biotechnol. 2013, 97, 87–98, doi:10.1007/s00253-012-4551-9.
[18]
Eckes, B.; Nischt, R.; Krieg, T. Cell-matrix interactions in dermal repair and scarring. Fibrogenesis Tissue Repair 2010, 3, doi:10.1186/1755-1536-3-4.
[19]
Wang, G.; Hosaka, T.; Ochi, K. Dramatic activation of antibiotic production in Streptomyces coelicolor by cumulative drug resistance mutations. Appl. Environ. Microbiol. 2008, 74, 2834–2340, doi:10.1128/AEM.02800-07.
[20]
Xu, J.; Tozawa, Y.; Lai, C.; Hayashi, H.; Ochi, K. A rifampicin resistance mutation in the rpoB gene confers ppGpp-independent antibiotic production in Streptomyces coelicolor A3(2). Mol. Genet. Genomics 2002, 268, 179–189, doi:10.1007/s00438-002-0730-1.
[21]
Okamoto-Hosoya, Y.; Okamoto, S.; Ochi, K. Development of antibiotic-overproducing strains by site-directed mutagenesis of the rpsL gene in Streptomyces lividans. Appl. Environ. Microbiol. 2003, 69, 4256–4259, doi:10.1128/AEM.69.7.4256-4259.2003.
[22]
Hu, H.; Ochi, K. Novel approach for improving the productivity of antibiotic-producing strains by inducing combined resistant mutations. Appl. Environ. Microbiol. 2001, 67, 1885–1892, doi:10.1128/AEM.67.4.1885-1892.2001.
[23]
Hesketh, A.; Ochi, K. A novel method for improving Streptomyces coelicolor A3(2) for production of actinorhodin by introduction of rpsL (encoding ribosomal protein S12) mutations conferring resistance to streptomycin. J. Antibiot. (Tokyo) 1997, 50, 532–535, doi:10.7164/antibiotics.50.532.
[24]
Okamoto-Hosoya, Y.; Sato, T.A.; Ochi, K. Resistance to paromomycin is conferred by rpsL mutations, accompanied by an enhanced antibiotic production in Streptomyces coelicolor A3(2). J. Antibiot. (Tokyo) 2000, 53, 1424–1427, doi:10.7164/antibiotics.53.1424.
[25]
Shima, J.; Hesketh, A.; Okamoto, S.; Kawamoto, S.; Ochi, K. Induction of actinorhodin production by rpsL (encoding ribosomal protein S12) mutations that confer streptomycin resistance in Streptomyces lividans and Streptomyces coelicolor A3(2). J. Bacteriol. 1996, 178, 7276–7284.
[26]
Wilkinson, C.J.; Hughes-Thomas, Z.A.; Martin, C.J.; Bohm, I.; Mironenko, T.; Deacon, M.; Wheatcroft, M.; Wirtz, G.; Staunton, J.; Leadlay, P.F. Increasing the efficiency of heterologous promoters in actinomycetes. J. Mol. Microbiol. Biotechnol. 2002, 4, 417–426.
